Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Other hematologic neoplasm 3Other solid neoplasm 2Myeloid 2Gastrointestinal 2CNS 2Head & Neck 1Dermatologic 1Breast 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Pancreatic Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1

Interventions

Cyclophosphamide 259fludarabine phosphate 232Azacitidine 180fludarabine 179Busulfan 174Cytarabine 154Mycophenolic Acid 147Tacrolimus 145Whole-Body Irradiation 141Imatinib Mesylate 141Peripheral Blood Stem Cell Transplantation 139Cyclosporine 110Antilymphocyte Serum 108Melphalan 106Methotrexate 105Filgrastim 101Decitabine 98nilotinib 82venetoclax 77ruxolitinib 72Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 62Dasatinib 62Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × bemcentinib × Myeloid × Clear all
NCT06469138 2025-01-29

8479217

BerGenBio ASA

Phase 1 Completed
6 enrolled 17 charts
CNSDermatologicGastrointestinalMyeloidOther hematologic neoplasmOther solid neoplasmThoracic

Mesothelioma, Malignant, COVID-19, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Leukemia, Myeloid, Acute

NCT02488408 2024-12-19

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

BerGenBio ASA

Phase 1/2 Completed
122 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡